Observational Study
Copyright ©The Author(s) 2020.
World J Gastrointest Pathophysiol. Apr 12, 2020; 11(2): 32-42
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Figure 2
Figure 2 Flow chart depicting the switch to alternative aminosalicylate resulting from the balsalazide shortage, with adverse effect rate of 35. 5% occurring immediately post-switch, which in all cases resolved upon return to balsalazide.